EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Primary physiology and guidance Peer-reviewed human data Schematics and models

ADME, PK and PBPK

What the body does to a botanical compound between the dose and the tissue, and the equations and physiological models that describe it. Each value is tied to the primary source it came from.

25.5%of resting cardiac output reaches the liver in the ICRP reference adult male: 6.5% by the hepatic artery, the rest by the portal vein
≈32 m²mean mucosal surface of the whole digestive tract, about 2 m² of it in the large intestine
≈80%CYP3A share of immunoquantified cytochrome P450 in human small-intestinal mucosa (31 donors)
−79.4%oral midazolam AUC after 14 days of a St John's wort extract supplying 41 mg/day hyperforin

ICRP Publication 89 (2002), Table 2.40; Helander and Fändriks, Scand J Gastroenterol 2014; Paine et al., Drug Metab Dispos 2006; Mueller et al., Eur J Clin Pharmacol 2006.

Status. EUTECNIQ is in formation and has no laboratory, studies or models running. The calculator and computed curves on this page are educational models, not predictions for any product or ingredient.

Related: Bioavailability design · Evidence and pharmacokinetics · Translational research · Dosage forms

Overview

ADME and the routes in

Absorption moves a compound from the dosing site into the blood. Distribution carries it to tissues, metabolism changes its structure, and excretion removes parent compound and metabolites. The route of entry decides whether the liver meets the dose before the rest of the body does.

An oral dose crosses the gut wall and travels in the hepatic portal vein to the liver, which can remove part of it on this first pass. Sublingual, buccal, inhaled and transdermal doses, and compounds carried in intestinal lymph, reach the systemic veins without passing the liver first.

Schematic, ADME: what the body does to a compound: Dose The route in Absorption From the dosing site into the blood Distribution Carried to tissues Metabolism Structure changed Excretion Parent and metabolites removed The route of entry decides whether the liver meets the dose before the rest of the body.
Schematic Drawn by EUTECNIQ from the text of this page. Organs are schematic, not an anatomical reference; Figure 1 below shows the routes.
An oral dose meets the gut wall and the liver before the rest of the body; sublingual, inhaled, transdermal and lymphatic entry do notAnatomical schematic; ICRP reference flows
Front-view schematic of an adult body showing where a botanical compound enters and leaves. The brain sits behind the blood-brain barrier; the heart and lungs are in the chest; the liver, stomach, small intestine (duodenum, jejunum, ileum), large intestine and kidneys are in the abdomen; skeletal muscle and subcutaneous adipose tissue are shown in the thighs and skin covers the body. Copper arteries and navy veins run as two trunks that supply every organ in parallel. An oral dose passes mouth, stomach and small intestine, crosses the gut wall, travels in the hepatic portal vein to the liver and only then reaches the systemic circulation. Sublingual and buccal absorption drains to the jugular veins, inhaled compounds enter pulmonary veins and transdermal compounds enter skin capillaries, all bypassing the liver's first pass; lipophilic compounds packed into chylomicrons leave the gut in lymph, which reaches the blood through the thoracic duct at the junction of the left subclavian and internal jugular veins. Elimination is shown by bile to feces, by the kidneys to urine and by enterohepatic recirculation. Liver enzymes CYP3A4, 2D6, 2C9, 2C19, 1A2 and 2E1, UGT and SULT, and intestinal efflux transporters P-gp and BCRP are labeled.
Schematic, not to scale. Flows: ICRP Publication 89 (2002), Table 2.40 (adult male); gastric pH: Evans et al., Gut 1988; transporter sites: Giacomini et al., Nat Rev Drug Discov 2010, Fig. 1; intestinal P450: Paine et al., Drug Metab Dispos 2006; lymph: Porter et al., Nat Rev Drug Discov 2007; Ilahi et al., StatPearls 2023. Illustration by EUTECNIQ. Full-size SVG
Text version of the drawing: the oral route, step by step
  1. MouthThe dose is swallowed; a sublingual or buccal dose would instead drain to the jugular veins.
  2. StomachThe dosage form disintegrates and dissolves at gastric pH 1.0–2.5.
  3. Small intestineDissolved compound crosses the gut wall, where CYP3A, UGT and the efflux pumps P-gp and BCRP act.
  4. Portal veinBlood from the stomach, intestines, spleen and pancreas carries the absorbed compound to the liver.
  5. LiverHepatocytes metabolize part of it and can excrete parent compound or conjugates into bile.
  6. Systemic circulationWhat escapes reaches the inferior vena cava, the heart and every organ in parallel.
The four ADME processes, where they happen and how they are measured
ProcessWhat happensMain sitesMeasured as
AbsorptionMovement from the dosing site into the bloodSmall intestine for oral doses; oral mucosa, lung or skin for other routesFraction absorbed Fa; absorption rate constant ka; tmax
DistributionReversible exchange between blood and tissuesAll perfused tissues; brain behind the blood–brain barrierVolume of distribution V; tissue-to-plasma ratio Kp; fraction unbound fu
MetabolismEnzymatic change in structure: phase I (mostly oxidation by CYPs), phase II (conjugation)Liver; gut wallIntrinsic clearance CLint; metabolite profile
ExcretionRemoval of parent compound and metabolitesKidneys (urine); liver (bile, then feces); lungs for volatile compoundsRenal and biliary clearance; recovery in urine and feces

Jones HM, Rowland-Yeo K. CPT Pharmacometrics Syst Pharmacol 2013;2:e63; Grogan S, Preuss CV. Pharmacokinetics. StatPearls, updated July 30, 2023; Zanger UM, Schwab M. Pharmacol Ther 2013;138:103–141.

Routes of entry, the vessel each enters, whether the liver is passed first, and the U.S. regulatory note
RouteEnters the blood throughLiver first?U.S. regulatory note
Oral, swallowedGut wall → hepatic portal vein → liverYesA dietary supplement must be “intended for ingestion” (21 U.S.C. 321(ff))
Sublingual, buccalOral mucosa → jugular veins → superior vena cavaNoFDA: sublingual products “are not dietary supplements and are not foods” (warning letter, Feb 5, 2019); buccal status depends on the intended absorption site
InhaledAlveoli → pulmonary veins → left heart → arteriesNoFDA has issued warning letters to inhaled caffeine products
TransdermalSkin → dermal capillaries → systemic veinsNoTransdermal and topical products “are not dietary supplements” (FDA warning-letter language)
Intestinal lymph (part of an oral dose)Lacteal → mesenteric lymph → thoracic duct → junction of the left subclavian and internal jugular veinsNoNot a separate route of administration; applies to highly lipophilic compounds (section 2)

ICRP Publication 89 (2002), §7.7 (portal circulation); Ilahi M, et al. Anatomy, Thorax, Thoracic Duct. StatPearls, updated July 24, 2023; 21 U.S.C. 321(ff); FDA warning letter 566205 (DK Vitamins), Feb 5, 2019; Gaffney A. Regulatory Focus (RAPS), June 6, 2013. Dosage-form status in detail: Dosage forms.

Gut

The gastrointestinal tract

Most oral absorption happens in the small intestine, which is long, close to neutral and folded into a large surface. Gastric emptying and small-intestinal transit set how long a dissolved compound has to cross the wall; the colon holds contents far longer but has a much smaller surface.

Length, pH and transit time of each segment of the adult gastrointestinal tract
SegmentLength, cm (adult male)Luminal pH, mean (SD)Transit time (adult male)
Mouth——Solids 15 s; liquids 2 s
Esophagus28—Solids 8 s (fast 90% of the bolus)
Stomach—1.0–2.5 (range, all subjects)Solids 75 min; caloric liquids 45 min; non-caloric liquids 30 min
Small intestine2806.6 (0.5) proximal, first hour; 7.5 (0.4) terminal ileum4 h
Duodenum, jejunum, ileum≈22, ≈104, ≈154 (8%, 37%, 55%)——
Large intestine110 (right colon 34, left colon 38, rectosigmoid 38)6.4 (0.4) cecum; 7.0 (0.7) left colonRight colon 12 h; left colon 12 h; rectosigmoid 12 h

Lengths and transit: ICRP Publication 89 (2002), Tables 2.11 and 2.37 and §6.3.10 (segment percentages; segment lengths computed from them). pH: Evans DF, et al. Gut 1988;29:1035–1041 (66 subjects, radiotelemetry capsule). Female transit times differ (stomach solids 105 min; each colon segment 16 h).

Surface area of the human gut mucosa
MeasureValue
Mean total mucosal surface, whole digestive tract≈32 m², of which ≈2 m² in the large intestine
Surface amplification, small intestinePlicae circulares ≈1.6×; villi and microvilli together 60–120×
Mean inner diameterSmall intestine 2.5 cm; large intestine 4.8 cm
Oro-anal length, intubation and radiology≈5 m, about two thirds of it small intestine

Helander HF, Fändriks L. Scand J Gastroenterol 2014;49:681–689. The textbook figure of 260–300 m² (“a tennis court”) is not supported by their morphometry.

Highly lipophilic compounds can leave the enterocyte inside chylomicrons. These lipoproteins enter the lacteal, not the blood capillary, so the compound reaches the blood through the thoracic duct and escapes the liver's first pass.

Six ways across the gut wall: most absorbed compound leaves in portal blood, chylomicron cargo leaves in lymphCell schematic
Schematic of five small-intestinal absorptive cells between the lumen above and the lamina propria below. Numbered paths show: 1, passive diffusion through the cell; 2, paracellular passage between cells through the tight junctions; 3, carrier-mediated uptake by apical transporters such as PEPT1, OATP and MCT1; 4, efflux back to the lumen by P-gp, BCRP and MRP2 on the apical membrane; 5, metabolism inside the cell by CYP3A and UGT, with conjugates leaving through MRP3 on the basolateral side; 6, incorporation of highly lipophilic compounds into chylomicrons, which are too large for blood capillaries and enter the lacteal, so they reach the blood through the lymph and bypass the liver's first pass. Most absorbed compounds enter the blood capillary and travel to the liver in the portal vein.
Schematic, not to scale. Transporter locations: Giacomini et al. (ITC), Nat Rev Drug Discov 2010, Fig. 1a; intestinal CYP3A: Paine et al., Drug Metab Dispos 2006; lymphatic route: Porter et al., Nat Rev Drug Discov 2007; villus lacteal: ICRP Publication 89 §6.3.10; pH: Evans et al., Gut 1988. Illustration by EUTECNIQ. Full-size SVG
Text version of the drawing: six ways across the gut wall

1, passive diffusion through the cell; 2, paracellular passage through tight junctions; 3, uptake by apical carriers such as PEPT1, OATP and MCT1; 4, efflux back to the lumen by P-gp, BCRP and MRP2; 5, metabolism by CYP3A and UGT inside the cell, with conjugates leaving through basolateral MRP3; 6, incorporation into chylomicrons and exit to the lacteal.

Criteria and anatomy of intestinal lymphatic transport
ItemValueCaveat
Lipophilicity of lymph-transported drugsTypically log P > 5A guide, not a threshold
Solubility in long-chain triglycerideTypically > 50 mg/g“Not an absolute requirement”: two CETP inhibitors in dogs were mainly lymph-transported, one below 50 mg/g
Thoracic ductBegins at the cisterna chyli (L2); 38–45 cm long; empties at the junction of the left subclavian and internal jugular veinsAnatomical variants occur

Porter CJH, Trevaskis NL, Charman WN. Nat Rev Drug Discov 2007;6:231–248 (criteria from Charman and Stella, Int J Pharm 1986); Trevaskis NL, et al. Pharm Res 2010;27:878–893; Ilahi M, et al. StatPearls, Thoracic Duct, 2023.

Physicochemistry

Properties that predict absorption

Five molecular properties do most of the work: water solubility; lipophilicity, as log P for the neutral form or log D at a stated pH; the pKa of ionizable groups; molecular size; and polar surface area. Rules built on them flag likely permeability problems. They say nothing about metabolism.

Curcumin meets the Lipinski and Veber limits below, yet after 10 g and 12 g oral doses free curcumin was detected in only one of twelve subjects, while its glucuronide and sulfate conjugates were found in all. Low water solubility and extensive conjugation, not membrane permeation, limit exposure to the parent compound.

Rules and classification systems for oral absorption and brain penetration
RuleCriteriaBuilt from
Lipinski “rule of 5”Poor absorption or permeation more likely with > 5 H-bond donors, > 10 H-bond acceptors, molecular weight > 500, or CLogP > 5 (MLogP > 4.15)Discovery compounds, Pfizer
Veber≤ 10 rotatable bonds and polar surface area ≤ 140 Ų (or ≤ 12 H-bond donors plus acceptors)Oral bioavailability in rats, > 1,100 candidates, GSK
BCS, ICH M9Highly soluble: highest single therapeutic dose dissolves in ≤ 250 mL over pH 1.2–6.8 at 37 ± 1 °C. Highly permeable: absolute bioavailability ≥ 85%, or ≥ 85% of the dose recovered in urine as parent compound or phase 1 and phase 2 metabolites. Four classes from these two testsBiowaiver criteria for immediate-release oral drugs
CNS MPOSix properties (ClogP, ClogD7.4, MW, TPSA, H-bond donors, most basic pKa) combined into a 0–6 score119 marketed CNS drugs and 108 Pfizer CNS candidates

Lipinski CA, et al. Adv Drug Deliv Rev 2001;46:3–26; Veber DF, et al. J Med Chem 2002;45:2615–2623; ICH M9, Biopharmaceutics Classification System-Based Biowaivers, adopted November 20, 2019, §2.1–2.2; Wager TT, et al. ACS Chem Neurosci 2010;1:435–449; Vareed SK, et al. Cancer Epidemiol Biomarkers Prev 2008;17:1411–1417.

Three of ten botanical compounds break a Lipinski or Veber limit; curcumin and the permanently charged berberine break nonePubChem computed properties
Ten botanical compounds plotted by calculated lipophilicity (XLogP3) against topological polar surface area, with the Veber limit of 140 square angstroms and the Lipinski log P limit of 504080120160200TPSA, Ų0246810XLogP3 (calculated log P)log P > 5TPSA > 140 ŲCaffeine (CID 2519): XLogP3 -0.1, TPSA 58.4 Ų, MW 194.19, HBD 0, HBA 3, rotatable bonds 0CaffeineResveratrol (CID 445154): XLogP3 3.1, TPSA 60.7 Ų, MW 228.24, HBD 3, HBA 3, rotatable bonds 2ResveratrolQuercetin (CID 5280343): XLogP3 1.5, TPSA 127 Ų, MW 302.23, HBD 5, HBA 7, rotatable bonds 1QuercetinCurcumin (CID 969516): XLogP3 3.2, TPSA 93.1 Ų, MW 368.4, HBD 2, HBA 6, rotatable bonds 8CurcuminPiperine (CID 638024): XLogP3 3.5, TPSA 38.8 Ų, MW 285.34, HBD 0, HBA 3, rotatable bonds 3PiperineEGCG (CID 65064): XLogP3 1.2, TPSA 197 Ų, MW 458.4, HBD 8, HBA 11, rotatable bonds 4EGCGBerberine (cation) (CID 2353): XLogP3 3.6, TPSA 40.8 Ų, MW 336.4, HBD 0, HBA 4, rotatable bonds 2Berberine (cation)Hyperforin (CID 441298): XLogP3 9.6, TPSA 71.4 Ų, MW 536.8, HBD 1, HBA 4, rotatable bonds 11HyperforinHypericin (CID 3663): XLogP3 5.7, TPSA 156 Ų, MW 504.4, HBD 6, HBA 8, rotatable bonds 0Hypericin(−)-Hydrastine (CID 197835): XLogP3 2.7, TPSA 66.5 Ų, MW 383.4, HBD 0, HBA 7, rotatable bonds 3(−)-Hydrastinemeets Lipinski and Veberbreaks at least one limitTen botanical compounds plotted by calculated lipophilicity (XLogP3) against topological polar surface area, with the Veber limit of 140 square angstroms and the Lipinski log P limit of 504080120160200TPSA, Ų0246810XLogP3 (calculated log P)log P > 5TPSA > 140 ŲCaffeine (CID 2519): XLogP3 -0.1, TPSA 58.4 Ų, MW 194.19, HBD 0, HBA 3, rotatable bonds 0CaffeineResveratrol (CID 445154): XLogP3 3.1, TPSA 60.7 Ų, MW 228.24, HBD 3, HBA 3, rotatable bonds 2ResveratrolQuercetin (CID 5280343): XLogP3 1.5, TPSA 127 Ų, MW 302.23, HBD 5, HBA 7, rotatable bonds 1QuercetinCurcumin (CID 969516): XLogP3 3.2, TPSA 93.1 Ų, MW 368.4, HBD 2, HBA 6, rotatable bonds 8CurcuminPiperine (CID 638024): XLogP3 3.5, TPSA 38.8 Ų, MW 285.34, HBD 0, HBA 3, rotatable bonds 3PiperineEGCG (CID 65064): XLogP3 1.2, TPSA 197 Ų, MW 458.4, HBD 8, HBA 11, rotatable bonds 4EGCGBerberine (cation) (CID 2353): XLogP3 3.6, TPSA 40.8 Ų, MW 336.4, HBD 0, HBA 4, rotatable bonds 2BerberineHyperforin (CID 441298): XLogP3 9.6, TPSA 71.4 Ų, MW 536.8, HBD 1, HBA 4, rotatable bonds 11HyperforinHypericin (CID 3663): XLogP3 5.7, TPSA 156 Ų, MW 504.4, HBD 6, HBA 8, rotatable bonds 0Hypericin(−)-Hydrastine (CID 197835): XLogP3 2.7, TPSA 66.5 Ų, MW 383.4, HBD 0, HBA 7, rotatable bonds 3(−)-Hydrastinemeets Lipinski and Veberbreaks a limit
PubChem compound records (computed XLogP3, TPSA, H-bond donors and acceptors, rotatable bonds, molecular weight), retrieved October 27, 2026. Lipinski used CLogP; XLogP3 is a different calculated log P, so values near 5 are approximate.
Show data: properties and rule checks for the ten compounds
PubChem computed properties of ten botanical compounds and their Lipinski and Veber checks
CompoundPubChem CIDMW, g/molXLogP3TPSA, ŲHBDHBARotatable bondsLipinski violationsVeber met
Caffeine2519194.19−0.158.40300yes
Resveratrol445154228.243.160.73320yes
Quercetin5280343302.231.51275710yes
Curcumin969516368.43.293.12680yes
Piperine638024285.343.538.80330yes
EGCG65064458.41.219781142 (HBD, HBA)no (TPSA)
Berberine (cation, charge +1)2353336.43.640.80420yes
Hyperforin441298536.89.671.414112 (MW, log P)no (rotatable bonds)
Hypericin3663504.45.71566803 (HBD, MW, log P)no (TPSA)
(−)-Hydrastine197835383.42.766.50730yes

PubChem, National Center for Biotechnology Information, compound records by CID, retrieved October 27, 2026. Rule checks computed on this page from those values.

Metabolism

First pass and the enzymes

Oral bioavailability is a product of three fractions: absorbed (Fa), escaping the gut wall (Fg) and escaping the liver (Fh). In the well-stirred liver model, hepatic extraction is EH = fu·CLint / (QH + fu·CLint), with Fh = 1 − EH.

With the ICRP reference liver blood flow of 99.5 L/h, a compound whose unbound intrinsic clearance equals that flow loses half of what reaches the liver. As fu·CLint grows far beyond QH, hepatic clearance approaches liver blood flow.

Once unbound intrinsic clearance passes liver blood flow, most of each pass through the liver is lostComputed, well-stirred model
Fraction escaping the liver, F_h, against unbound intrinsic clearance in the well-stirred model, for hepatic blood flow 99.5 L/h00.250.50.751Fh​ = 1 − EH​1101001,00010,000fu​ · CLint​, L/h (blood basis)F_h = Q_H / (Q_H + fu·CLint)f_u·CL_int = Q_H = 99.5 L/h gives F_h = 0.5fu​·CLint​ = QH​ = 99.5 L/h → Fh​ = 0.5Fraction escaping the liver, F_h, against unbound intrinsic clearance in the well-stirred model, for hepatic blood flow 99.5 L/h00.250.50.751Fh​ = 1 − EH​1101001,00010,000fu​ · CLint​, L/h (blood basis)F_h = Q_H / (Q_H + fu·CLint)f_u·CL_int = Q_H = 99.5 L/h gives F_h = 0.5fu​·CLint​ = QH​= 99.5 L/h givesFh​ = 0.5
Fh = QH/(QH + fu·CLint) (Pang KS, Rowland M. J Pharmacokinet Biopharm 1977;5:625–653). QH = 6.5 L/min × 25.5% × 60 = 99.5 L/h blood flow, ICRP Publication 89, Tables 2.39 and 2.40 (adult male). Blood-basis clearance; illustrative.
Phase I and phase II enzymes and efflux transporters, where they act, and FDA example substrates, inhibitors and inducers
Enzyme or transporterReaction or roleWhere, and variabilityFDA sensitive substrate (example)FDA strong inhibitor or inducer (examples)
CYP3A4Phase I oxidationAmong the most highly expressed liver CYPs; ≈80% of intestinal P450MidazolamInhibitors: ketoconazole, itraconazole, clarithromycin. Inducers: rifampin, St John's wort
CYP2D6Phase I oxidationLess abundant in liver; polymorphic (poor to ultrarapid metabolizers)Desipramine, dextromethorphanInhibitors: fluoxetine, paroxetine, quinidine, bupropion. No strong inducer listed
CYP2C9Phase I oxidationHighly expressed in liver; ≈15% of intestinal P450; polymorphicCelecoxibNone listed as strong
CYP2C19Phase I oxidationLess abundant in liver; polymorphicOmeprazole, S-mephenytoinInhibitors: fluconazole, fluoxetine, fluvoxamine. Inducer: rifampin
CYP1A2Phase I oxidationHighly expressed in liver; not or only faintly detected in intestineCaffeine, melatoninInhibitor: fluvoxamine
CYP2E1Phase I oxidationHighly expressed in liver; not or only faintly detected in intestineNot in the FDA table—
UGTPhase II glucuronidation (UDP-glucuronic acid donor)22 human proteins; liver has the most, with significant extrahepatic expression——
SULTPhase II sulfation (PAPS donor)Cytosolic family; usually detoxifying, sometimes bioactivating——
P-gp (ABCB1)ATP-dependent effluxLuminal membrane of intestine and blood–brain barrier; canalicular membrane of hepatocytes; kidneyDigoxin, dabigatran etexilate, fexofenadineInhibitors: itraconazole, quinidine, clarithromycin
BCRP (ABCG2)ATP-dependent effluxApical membrane of intestine; blood–brain barrier; canalicular membraneRosuvastatin, sulfasalazineInhibitors include curcumin and cyclosporine

Zanger UM, Schwab M. Pharmacol Ther 2013;138:103–141 (expression and polymorphism); Paine MF, et al. Drug Metab Dispos 2006;34:880–886 (intestinal P450, 31 donors); Rowland A, et al. Int J Biochem Cell Biol 2013;45:1121–1132; Coughtrie MWH. Chem Biol Interact 2016;259:2–7; Giacomini KM, et al. Nat Rev Drug Discov 2010;9:215–236; U.S. FDA, Examples of Drugs that Interact with CYP Enzymes and Transporter Systems, content current as of May 29, 2026 (Tables 1–3). FDA groups CYP3A4 and CYP3A5 as “CYP3A”.

Brain

The blood–brain barrier

Brain capillary endothelial cells are sealed to each other by tight junctions, carry efflux pumps such as P-gp and BCRP on the blood-facing membrane, and are covered by pericytes and astrocyte end-feet. A compound reaches brain tissue mainly by diffusing through these cells or by riding an uptake transporter.

Once there, the unbound concentration at the target sets receptor occupancy by mass action. The CNS MPO score summarizes six properties that favor entry; in its original analysis, 74% of 119 marketed CNS drugs scored 4 or more out of 6, against 60% of 108 Pfizer CNS candidates.

Tight junctions close the gaps between brain endothelial cells, efflux pumps return substrates to blood, and occupancy follows mass actionSchematic; computed occupancy
Two schematics. Left: a brain capillary in cross-section. Endothelial cells form the wall and are sealed to each other by tight junctions, so solutes cannot pass between them; a basement membrane, a pericyte and astrocyte end-feet surround the vessel. Lipophilic small molecules can diffuse through the endothelial cells; P-gp and BCRP on the luminal membrane pump substrates back into the blood; OATP uptake transporters carry some solutes in. Right: a ligand binding a receptor on a neuron by the law of mass action. Fractional occupancy equals C divided by C plus K_D, so it is 9% at one tenth of K_D, 50% at K_D and 91% at ten times K_D.
Schematic, not to scale. Abbott et al., Neurobiol Dis 2010; Giacomini et al. (ITC), Nat Rev Drug Discov 2010, Fig. 1d; Chou, Pharmacol Rev 2006. Occupancy values computed from θ = C/(C + KD). Illustration by EUTECNIQ. Full-size SVG
Text version of the drawing

Panel A: a brain capillary in cross-section, with four paths: passive diffusion through the endothelium; the paracellular route, closed by tight junctions; efflux to blood by P-gp and BCRP; and uptake by OATP1A2 and OATP2B1. Panel B: fractional occupancy θ = C/(C + KD) gives 9%, 50% and 91% at C equal to 0.1, 1 and 10 times KD.

The six properties in the CNS MPO score and what each represents
CNS MPO propertyWhat it represents
ClogPCalculated lipophilicity of the neutral molecule
ClogD at pH 7.4Calculated distribution coefficient, counting ionized forms at blood pH
Molecular weightSize
Topological polar surface areaPolarity, from N and O atoms and their hydrogens
H-bond donorsNumber of donor groups
Most basic pKaIonization of the most basic center

Abbott NJ, et al. Neurobiol Dis 2010;37:13–25; Giacomini KM, et al. Nat Rev Drug Discov 2010;9:215–236, Fig. 1d; Wager TT, et al. ACS Chem Neurosci 2010;1:435–449. Higher scores also aligned with favorable permeability, P-gp efflux, metabolic stability and safety attributes in that analysis.

Pharmacokinetics

Concentration over time

A one-compartment model treats the body as one well-mixed volume. Clearance (CL) sets how fast the compound is removed; the volume of distribution (V) relates the amount in the body to the plasma concentration. Their ratio is the elimination rate constant k = CL/V, and the half-life is t½ = ln 2 · V/CL.

After an oral dose with first-order absorption and bioavailability F, total exposure is AUC = F·Dose/CL, whatever V and ka are. Repeated doses accumulate until, after four to five half-lives, intake and elimination balance.

One-compartment pharmacokinetic equations
QuantityEquation
Elimination rate constant, 1/hk = CL / V
Half-life, ht½ = ln 2 / k = 0.693 · V / CL
Intravenous bolusC(t) = (Dose / V) · e−kt
Oral dose, first-order absorption (ka ≠ k)C(t) = F·Dose·ka / [V(ka − k)] · (e−kt − e−kat)
Time of the peaktmax = ln(ka/k) / (ka − k)
ExposureAUC0–∞ = F · Dose / CL
Absolute bioavailabilityF = (AUCoral · DoseIV) / (AUCIV · Doseoral)
Accumulation ratio, dosing interval τR = 1 / (1 − e−kτ)

Grogan S, Preuss CV. Pharmacokinetics. StatPearls, updated July 30, 2023 (definitions of half-life, volume, clearance, bioavailability; steady state in four to five half-lives); Mould DR, Upton RN. CPT Pharmacometrics Syst Pharmacol 2013;2:e38 (first-order absorption; “flip-flop” kinetics when absorption is slower than elimination). Remaining expressions follow algebraically from the oral equation.

Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.

One-compartment oral model, repeated doses by superpositionC(t) = Σi C1(t − iτ)
Half-life t½
First-dose Cmax at tmax
AUC0–∞ per dose
Accumulation ratio R

Plasma concentration after the chosen dosing scheduleIllustrative inputs
Show data
Concentration at selected times for the chosen inputs
Time, hConcentration, mg/L
00
Equations in the table above. Default inputs are invented for illustration and describe no botanical compound.
Method, assumptions and limits: concentration–time calculator
What it calculates
Plasma concentration after one or more equal oral doses in a one-compartment model with first-order absorption and elimination, summed by superposition.
Equations
k = CL/V; t½ = ln 2/k; per dose Ci(t) = F·D·ka/[V(ka − k)]·(e−k(t−ti) − e−ka(t−ti)) for t ≥ ti; when ka = k, Ci(t) = F·D·k·(t − ti)·e−k(t−ti)/V; AUC0–∞ = F·D/CL; R = 1/(1 − e−kτ).
Units
Dose in mg, CL in L/h, V in L, so concentration is in mg/L (equal to µg/mL); time in hours.
Assumptions
Linear kinetics; one well-mixed compartment; no lag time; constant F; parent compound only.
What it does not establish
It does not describe any botanical constituent, and it ignores metabolites, which for compounds such as curcumin carry most of the measured exposure.
Pharmacodynamics

Concentration to effect

The sigmoid Emax (Hill) model links concentration to effect: E = E0 + Emax·Cn/(EC50n + Cn). EC50 is the concentration giving half the maximal effect; the Hill coefficient n sets the steepness. With n = 1 it has the same form as mass-action binding.

A steep curve covers the whole response in a narrow concentration range, so a change in exposure, for example from an interaction, moves the effect more.

All Hill curves cross half-maximal effect at EC50; the coefficient n decides how fast they get thereComputed curves
Effect as a fraction of maximum against concentration relative to EC50, for Hill coefficients 0.5, 1, 2 and 400.250.50.751E / Emax​0.0010.010.11101001000C / EC50​n = 0.5n = 1n = 2n = 4n = 0.5n = 1n = 2n = 4all curves pass through E = Emax/2 at C = EC50Effect as a fraction of maximum against concentration relative to EC50, for Hill coefficients 0.5, 1, 2 and 400.250.50.751E / Emax​0.0010.010.11101001000C / EC50​n = 0.5n = 1n = 2n = 4n = 0.5n = 1n = 2n = 4all curves pass through E = Emax/2 at C = EC50
E/Emax = Cn/(EC50n + Cn) with E0 = 0. Holford NHG, Sheiner LB. Clin Pharmacokinet 1981;6:429–453; Chou T-C. Pharmacol Rev 2006;58:621–681 (Hill equation from the mass-action law).
Concentration range needed to move from 10% to 90% of maximal effect for four Hill coefficients
Hill coefficient nC90/C10 (concentration range from 10% to 90% of Emax)
0.56,561-fold
181-fold
29-fold
43-fold

Computed: C90/C10 = 811/n, from the Hill equation solved for C at E/Emax = 0.1 and 0.9.

PBPK

Physiologically based models

A PBPK model represents organs as compartments with measured volumes and blood flows, connected in parallel between arterial and venous blood, with the lungs in series and the gut, spleen and pancreas draining to the liver. For a perfusion-limited tissue, VT·dCT/dt = QT·(CA − CT·B:P/Kp). Drug-specific inputs such as Kp, fu and CLint then give concentration–time curves in each tissue.

Regulators judge PBPK analyses case by case. FDA's 2018 guidance sets the format of a PBPK report; EMA's guideline, in effect since July 1, 2019, also asks that the modeling platform be qualified for its intended use.

Every tissue draws arterial blood in parallel; only the liver also receives the gut's venous outflowICRP Publication 89 reference values
PBPK model structure: venous and arterial blood pools joined through the lungs; each tissue is fed in parallel from arterial blood and drains to venous blood; gut, spleen and pancreas drain through the portal vein into the liver; flows are percent of cardiac output for the ICRP Publication 89 adult maleAll of the cardiac output passes the lungsLungs: 100% of cardiac outputVenous bloodArterial bloodEach tissue: arterial in (right), venous out (left)Brain: 12% of cardiac output, 0.78 L/minBrain12%Heart (coronary): 4% of cardiac output, 0.26 L/minHeart (coronary)4%Kidneys: 19% of cardiac output, 1.24 L/minKidneys19%Skeletal muscle: 17% of cardiac output, 1.11 L/minSkeletal muscle17%Adipose tissue: 5% of cardiac output, 0.33 L/minAdipose tissue5%Skin: 5% of cardiac output, 0.33 L/minSkin5%Skeleton: 5% of cardiac output, 0.33 L/minSkeleton5%Other tissues: 7.5% of cardiac output, 0.49 L/minOther tissues7.5%Stomach, esophagus: 1% of cardiac output; venous outflow to the portal veinStomach, esophagus1%Small intestine: 10% of cardiac output; venous outflow to the portal veinSmall intestine10%Large intestine: 4% of cardiac output; venous outflow to the portal veinLarge intestine4%Spleen: 3% of cardiac output; venous outflow to the portal veinSpleen3%Pancreas: 1% of cardiac output; venous outflow to the portal veinPancreas1%portal vein 19%Liver: hepatic artery 6.5% plus portal 19% = 25.5% of cardiac outputLiver: 25.5% total6.5% hepatic artery + 19% portalCLH​Percent of cardiac output (6.5 L/min), ICRP Publication 89, Table 2.40PBPK model structure: venous and arterial blood pools joined through the lungs; each tissue is fed in parallel from arterial blood and drains to venous blood; gut, spleen and pancreas drain through the portal vein into the liver; flows are percent of cardiac output for the ICRP Publication 89 adult maleAll of the cardiac output passes the lungsLungs: 100% of cardiac outputVenous bloodArterial bloodArterial in, venous outBrain: 12% of cardiac output, 0.78 L/minBrain12%Heart (coronary): 4% of cardiac output, 0.26 L/minHeart (coronary)4%Kidneys: 19% of cardiac output, 1.24 L/minKidneys19%Skeletal muscle: 17% of cardiac output, 1.11 L/minSkeletal muscle17%Adipose tissue: 5% of cardiac output, 0.33 L/minAdipose tissue5%Skin: 5% of cardiac output, 0.33 L/minSkin5%Skeleton: 5% of cardiac output, 0.33 L/minSkeleton5%Other tissues: 7.5% of cardiac output, 0.49 L/minOther tissues7.5%Stomach, esophagus: 1% of cardiac output; venous outflow to the portal veinStomach, esophagus1%Small intestine: 10% of cardiac output; venous outflow to the portal veinSmall intestine10%Large intestine: 4% of cardiac output; venous outflow to the portal veinLarge intestine4%Spleen: 3% of cardiac output; venous outflow to the portal veinSpleen3%Pancreas: 1% of cardiac output; venous outflow to the portal veinPancreas1%portal vein 19%Liver: hepatic artery 6.5% plus portal 19% = 25.5% of cardiac outputLiver: 25.5% total6.5% artery + 19% portalCLH​% of 6.5 L/min, ICRP 89
Structure after Jones HM, Rowland-Yeo K. CPT Pharmacometrics Syst Pharmacol 2013;2:e63, Fig. 1. Flows: ICRP Publication 89 (2002), Table 2.40, adult male; “other tissues” sums bronchial (2.5%), thyroid, lymph nodes, adrenals, gonads, bladder and remaining tissues (7.5%).
ICRP Publication 89 reference organ masses and blood flows for the adult male
TissueMass, g (adult male)Blood flow, % of cardiac output (male / female)Blood flow, L/min (male, computed)
Liver1,80025.5 / 27.0 total (6.5 arterial)1.66
Kidneys (2)31019 / 171.24
Skeletal muscle29,00017 / 121.11
Brain1,45012 / 120.78
Small intestine (wall)65010 / 110.65
Adipose tissue18,2005.0 / 8.50.33
Skin3,3005.0 / 5.00.33
Heart (tissue; coronary flow)3304.0 / 5.00.26
Large intestine (wall)3704.0 / 5.00.26
Spleen1503.0 / 3.00.20
Lungs (tissue; bronchial flow)5002.5 / 2.5 (all cardiac output passes the pulmonary circulation)0.16
Stomach and esophagus (wall)150 (stomach)1.0 / 1.00.065
Pancreas1401.0 / 1.00.065

ICRP Publication 89 (2002): Table 2.8 (masses), Table 2.39 (cardiac output 6.5 L/min male, 5.9 L/min female), Table 2.40 (flows); reference body mass 73 kg male, 60 kg female (Table 2.9). L/min computed as 6.5 × percentage. Large-intestine wall: right colon 150 + left colon 150 + rectosigmoid 70 g.

FDA and EMA guidance on PBPK analyses
DocumentDates and statusWhat it covers
FDA, Physiologically Based Pharmacokinetic Analyses — Format and Content (docket FDA-2016-D-3969)September 2018; final guidance, CDERA six-section PBPK study report: executive summary, introduction, materials and methods, results, discussion, appendices. Does not address modeling methods; acceptance in place of clinical data is decided case by case
EMA, Guideline on the reporting of PBPK modelling and simulation (EMA/CHMP/458101/2016)Adopted by CHMP December 13, 2018; in effect July 1, 2019Report content, and qualification of the PBPK platform for the intended purpose with requirements scaled to regulatory impact; applies to commercial and in-house platforms

U.S. FDA guidance page, content current as of October 18, 2019; EMA guideline PDF, cover page and sections 1–4 and Appendix 1. Teorell introduced physiological multicompartment models in 1937 (Jones and Rowland-Yeo 2013).

Bioavailability

Raising exposure: the human data

The often-quoted “2000%” for piperine comes from a 1998 study in ten healthy men given 2 g curcumin with or without 20 mg piperine. Serum curcumin after curcumin alone was undetectable or very low, so the percentage is relative to a baseline mostly below detection.

Later formulation studies report fold-increases in curcuminoids measured after enzymatic deconjugation, which counts glucuronide and sulfate metabolites with the parent. A higher plasma AUC is a pharmacokinetic result; it does not show an effect. Full comparison: what curcumin studies measured.

Human pharmacokinetic studies of three curcumin bioavailability approaches
StudyDesignWhat was measuredReported resultRead with
Shoba et al. 1998: piperine co-doseTen healthy men; 2 g curcumin alone or with 20 mg piperineSerum curcumin“The increase in bioavailability was 2000%”; higher levels from 0.25 to 1 hBaseline mostly undetectable. Piperine inhibits glucuronidation (authors) and, in vitro, P-gp (IC50 15.5 µM, digoxin transport) and CYP3A4
Cuomo et al. 2011: phospholipid (lecithin) formulationRandomized, double-blind, crossover; formulation versus unformulated curcuminoidsPlasma curcumin, demethoxycurcumin, bisdemethoxycurcuminTotal curcuminoid absorption about 29-fold higherOnly phase 2 metabolites were detected; the main plasma curcuminoid was demethoxycurcumin, not curcumin
Purpura et al. 2018: γ-cyclodextrin formulation12 healthy adults, double-blind crossover; four productsTotal curcuminoids after β-glucuronidase/sulfatase hydrolysis, AUC0–12 h39.1-fold (γ-cyclodextrin), 8.5-fold (phytosome), 1.1-fold (turmeric-oil formulation) versus dose-normalized standard extractStandard extract given at about 5× the dose, then normalized; financial support from Wacker Chemie AG

Shoba G, et al. Planta Med 1998;64:353–356; Bhardwaj RK, et al. J Pharmacol Exp Ther 2002;302:645–650; Cuomo J, et al. J Nat Prod 2011;74:664–669; Purpura M, et al. Eur J Nutr 2018;57:929–938, Table 2.

Interactions

Botanical–drug interactions

A botanical can change exposure to a co-administered drug by inducing or inhibiting the enzymes and transporters above. FDA grades potency with sensitive substrates: a strong inducer lowers their AUC by at least 80%, a moderate one by 50–80%, a weak one by 20–50%; a strong inhibitor raises AUC at least 5-fold, a moderate one 2- to 5-fold, a weak one 1.25- to 2-fold.

St John's wort induction tracks hyperforin dose, and FDA notes that its effect “varies widely and is preparation dependent.” Goldenseal raised oral midazolam AUC by about 40–60%, mainly by inhibiting intestinal CYP3A.

The same plant moves from weak to near-strong CYP3A induction as hyperforin rises; goldenseal sits in the weak-inhibitor bandHuman pharmacokinetic studies
Change in oral midazolam AUC with four botanical preparations, against FDA potency categories for CYP3A inducers and inhibitorsstrongmoderateweakweakinduction (AUC falls)inhibition (AUC rises)St John's wort extract LI 160, hyperforin 41mg/daySt John's wort extract LI 160, hyperforin 41 mg/day: -79.4% (95% CI -88.6 to -70.1)−79.4%St John's wort powder, hyperforin 12 mg/daySt John's wort powder, hyperforin 12 mg/day: -47.9% (95% CI -59.7 to -36.2)−47.9%St John's wort powder, hyperforin 0.13 mg/daySt John's wort powder, hyperforin 0.13 mg/day: -21.1% (95% CI -33.9 to -8.3)−21.1%Goldenseal product, 16 adults (geometric meanratio 1.43)Goldenseal product, 16 adults (geometric mean ratio 1.43): +43.0% (90% CI +35.0 to +53.0)+43%-100%-80%-50%-20%0+25%+100%Change in midazolam AUCChange in oral midazolam AUC with four botanical preparations, against FDA potency categories for CYP3A inducers and inhibitorsstrongmoderateweakweakinduction (AUC falls)inhibition (AUC rises)SJW, hyperforin 41 mg/dSt John's wort extract LI 160, hyperforin 41 mg/day: -79.4% (95% CI -88.6 to -70.1)−79.4%SJW, hyperforin 12 mg/dSt John's wort powder, hyperforin 12 mg/day: -47.9% (95% CI -59.7 to -36.2)−47.9%SJW, hyperforin 0.13 mg/dSt John's wort powder, hyperforin 0.13 mg/day: -21.1% (95% CI -33.9 to -8.3)−21.1%GoldensealGoldenseal product, 16 adults (geometric mean ratio 1.43): +43.0% (90% CI +35.0 to +53.0)+43%-100%-50%0+50%+100%Change in midazolam AUC
Mueller SC, et al. Eur J Clin Pharmacol 2006;62:29–36 (AUC0–12 h, 95% CI); Nguyen JT, et al. Clin Pharmacol Ther 2021;109:1342–1352 (AUC0–∞ geometric mean ratio, 90% CI). Bands: FDA potency categories (Table 2 of the FDA interaction table, May 29, 2026). Points from different studies and designs; categories are defined for drugs, shown here for orientation.
Human studies of St John's wort and goldenseal with midazolam as a CYP3A probe
Preparation and studySubjectsProbeResult
St John's wort, six products for 14 days (Mueller 2006)42 healthy men, six parallel groupsOral midazolam 7.5 mgAUC0–12 h: −79.4% (hyperforin 41 mg/day), −47.9% (12 mg/day), −21.1% (0.13 mg/day). Decrease correlated with hyperforin dose (r = −0.765), not hypericin dose (r = −0.067)
St John's wort 300, 900, 1800 mg/day for 14 days (Hohmann 2024)11 healthy volunteersOral midazolam 30 µg; intravenous 10 µgOral clearance 1.96-, 3.86- and 5.62-fold; intravenous clearance 2.05-fold at 1800 mg/day; 17.5-fold oral with rifampin added. Effects mainly in the gut
Goldenseal product (Nguyen 2021)16 healthy volunteersProbe cocktail including midazolamMidazolam AUC0–∞ ratio 1.43 (90% CI 1.35–1.53); no effect on rosuvastatin or furosemide; metformin AUC ratio 0.77 (0.71–0.83)
Goldenseal 3 g once, or 1 g three times daily for 6 days (Nguyen 2023)Healthy adultsOral midazolamAUC and Cmax +40–60%, half-life up ≤ 23%; (−)-β-hydrastine the main precipitant; PBPK model within 20% of observed

Mueller SC, et al. 2006; Hohmann N, et al. Clin Transl Sci 2024;17:e70007; Nguyen JT, et al. Clin Pharmacol Ther 2021; Nguyen JT, et al. J Pharmacol Exp Ther 2023;387:252–264; U.S. FDA interaction table (St John's wort listed as a strong CYP3A inducer, footnote 18).

Combinations

Synergy, defined precisely

Two different things are both called synergy. A pharmacokinetic interaction changes exposure: one compound alters the absorption, metabolism or excretion of another, as piperine and St John's wort do. A pharmacodynamic interaction changes the response at a given exposure.

In pharmacology, synergy is a pharmacodynamic claim measured against a named model of no interaction. The 1992 Saariselkä agreement asks authors to say which: “Loewe synergy” or “Bliss synergy.”

Definitions and tests for drug interactions and synergy
TermDefinitionHow it is tested
Pharmacokinetic interactionOne agent changes the exposure (AUC, Cmax) to anotherClinical study with a probe substrate; FDA potency categories
Pharmacodynamic interactionThe combined response differs from the response expected without interactionDose–response curves for each agent alone and in combination
Loewe additivityEach agent acts as a dilution of the other; a combination is additive when dA/DA + dB/DB = 1Isobologram: the additive isobole is a straight line when relative potency is constant
Combination index (Chou–Talalay)CI = dA/DA + dB/DB; CI < 1 synergism, = 1 additive, > 1 antagonismMedian-effect analysis of single-agent and mixture dose–effect data
Bliss independenceAgents act independently; expected fractional effect EA + EB − EA·EBCompare observed with expected response at each dose pair

Tang J, Wennerberg K, Aittokallio T. Front Pharmacol 2015;6:181; Tallarida RJ. J Pharmacol Exp Ther 2006;319:1–7; Chou T-C. Pharmacol Rev 2006;58:621–681; Greco WR, Bravo G, Parsons JC. Pharmacol Rev 1995;47:331–385. DA, DB: doses of each agent alone giving the chosen effect; dA, dB: their doses in the mixture giving the same effect.

Below the additive line is synergy, above it antagonism, for the effect level chosenIllustrative points
Isobologram: the straight line of Loewe additivity joins the single-agent doses that give the same effect; a combination below the line is synergistic and one above it antagonistic00.51dB​ / DB​00.51dA​ / DA​synergy: CI = 0.25 + 0.25 = 0.5synergy, CI = 0.5additive: CI = 0.5 + 0.5 = 1additive, CI = 1antagonism: CI = 0.7 + 0.7 = 1.4antagonism, CI = 1.4Combination indexCI = dA​/DA​ + dB​/DB​DA​, DB​: doses of A or B alonethat give the chosen effectdA​, dB​: doses in the mixturethat give the same effectCI < 1 synergy · = 1 additive · > 1 antagonismIsobologram: the straight line of Loewe additivity joins the single-agent doses that give the same effect; a combination below the line is synergistic and one above it antagonistic00.51dB​ / DB​00.51dA​ / DA​synergy: CI = 0.25 + 0.25 = 0.5synergy, CI = 0.5additive: CI = 0.5 + 0.5 = 1additive, CI = 1antagonism: CI = 0.7 + 0.7 = 1.4antagonism, CI = 1.4
Isobologram for constant relative potency (Tallarida 2006); combination index after Chou 2006. Points are invented to show the three cases.
EUTECNIQ Proposed

Where EUTECNIQ would work

EUTECNIQ would characterize botanical constituents for the properties in section 3, measure exposure as parent compound and conjugates, and screen extracts against CYP3A and transporter probes before any human study. PBPK work would use qualified platforms and published physiology. None of this exists yet.

Related pages: Bioavailability design · Evidence and pharmacokinetics · Translational research · Combination science · Dosage forms

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.